

2024 Current Fiscal Year Report: The President's Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board

Report Run Date: 04/26/2024 12:07:47 PM

1. Department or Agency		2. Fiscal Year	
Department of State		2024	
3. Committee or Subcommittee		3b. GSA Committee No.	
The President's Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board		76050	
4. Is this New Fiscal Year?	5. Current Charter	6. Expected Renewal Date	7. Expected Term Date
No	02/27/2023	02/27/2025	
8a. Was Terminated During Fiscal Year?	8b. Specific Termination Authority		8c. Actual Term Date
No	Public Law 92-463, Section 14		
9. Agency Recommendation for Next Fiscal Year	10a. Legislation Req to Terminate?	10b. Legislation Pending?	
Continue	Not Applicable	Not Applicable	
11. Establishment Authority	Agency Authority		
12. Specific Establishment Authority	13. Effective Date	14. Committee Type	14c. Presidential?
Secretary of State and Department of State (Section 2656 of Title 22 of the United States Code)	12/05/2010	Continuing	No
15. Description of Committee Other Committee			
16a. Total Number of Reports	No Reports for this Fiscal Year		
17a. Open	17b. Closed	17c. Partially Closed	17d. Total
2	0	0	2

Meetings and Dates

Purpose	Start	End
SAB members discussed the management of non-communicable diseases (NCDs) among people with HIV, and integration of NCD with HIV programming; updates in HIV prevention science, and roll out of long-acting cabotegravir (CAB-LA); and PEPFAR 2023 strategic updates and the launch of the new Bureau of Global Health Security and Diplomacy (GHSD).	10/02/2023	10/02/2023
On April 5 from 8:40-5pm, the PEPFAR Scientific Advisory Board (SAB) discussed the implications of Dolutegravir resistance for PEPFAR; the role of long-acting agents for treatment in PEPFAR programs; updates on Lenacapavir and PEPFAR's scaleup plans; Behavioral Science Interventions; and advancing PEPFAR's Sustainability Agenda.	04/05/2024	04/05/2024

Number of Committee Meetings Listed: 2

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.00	\$0.00
18d. Total	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The Board serves the U.S. Global AIDS Coordinator ("the Coordinator") in a solely advisory capacity concerning scientific, implementation, and policy issues related to the global response to HIV/AIDS. These issues will be of concern as they influence the priorities and direction of PEPFAR evaluation and research, the content of national and international strategies and implementation, and the role of PEPFAR in the international discourse regarding appropriate and resourced responses. The committee accomplishes its purpose largely through the generation of recommendations.

20b. How does the Committee balance its membership?

The Board is composed of up to 50 members appointed by the Coordinator, representing non-U.S. Government personnel. All Board members are representative members. The membership is representative of the HIV/AIDS community, academia, international experts, partner government representatives, multilateral and bilateral agency representatives, foundations, advocates, and non-governmental organizations.

20c. How frequent and relevant are the Committee Meetings?

Original Estimated Number of Meetings per Year - 1 or 2 face-to-face meetings with teleconferences as needed. In order to keep committee meetings relevant and productive, working groups (subcommittees) have been formed that meet intermittently and on an ad-hoc basis. The ideas and advice generated by the working groups result in increased productivity and clearer recommendations produced by the whole

committee during face-to-face meetings.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The committee is necessary to keep PEPFAR programs at the forefront of scientific knowledge. The members of the committee have specific expertise which is relevant and crucial to PEPFAR in creating and implementing high-quality programs. The advice received by the Coordinator from the committee in the past fiscal year has assisted PEPFAR by informing next steps on how to swiftly pivot programs to achieve greater impact in response to new HIV normative guidance from the World Health Organization and others.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

This committee advises PEPFAR on science, implementation, and technical policy issues. Its function is best described as "Other" due to this broad scope. Further, this committee does not routinely produce formal reports, but does issue recommendations on policy decisions that are captured in the meeting minutes following each meeting. For a full meeting summary, including recommendations offered by the Board, please follow the link below where you may find past meeting minutes. Please see www.state.gov/scientific-advisory-board-pepfar/ Members' term end dates changed from the FY22 ACR to the FY23 ACR to reflect that membership lasts until the charter expires. The following subcommittees were retired as they were inactive in 2023 and 2024: (1) Finance and Economics Working Group; (2) HIV Prevention Continuum

Working Group; and (3) HIV Recency Testing.

Designated Federal Officer

Lindsey Yessick DFO

Committee Members	Start	End	Occupation	Member Designation
Abdool-Karim, Quarraisha	03/17/2017	02/27/2025	Associate Professor, Epidemiology, Mailman School of Public Health; Adjunct Professor, Public Health and Family Medicine, Nelson R. Mandela School of Medicine; Associate Scientific Director	Representative Member
Allen, David	10/01/2021	10/10/2023	Director	Representative Member
Auerbach, Judith	03/17/2017	02/27/2025	Professor, School of Medicine, Center for AIDS Prevention Studies	Representative Member
Berman, Peter	03/17/2017	02/27/2025	Professor of the Practice of Global Health Systems and Economics; Director, GHP Educational Initiatives	Representative Member
Breyer, Chris	10/01/2021	02/27/2025	Professor and Director	Representative Member
Celum, Connie	03/17/2017	02/27/2025	Professor, Allergy and Infectious Diseases, Global Health, and Adjunct Professor, Epidemiology	Representative Member

Currier, Judith	03/17/2017	02/27/2025	Chief, Division of Infectious Diseases, Professor of Medicine, David Geffen School of Medicine	Representative Member
Dhatt, Roopa	10/01/2021	02/27/2025	Executive Director	Representative Member
Fitzpatrick, Lisa	10/01/2021	02/27/2025	CEO, Director	Representative Member
Gruskin, Sofia	03/17/2017	02/27/2025	Professor of Preventive Medicine, Keck School of Medicine; Professor of Law and Preventive Medicine, Gould School of Law; Director, Program on Global Health and Human Rights, Institute for Global Health	Representative Member
Harrington, Mark	03/17/2017	02/27/2025	Executive Director	Representative Member
Kanyoro, Musimbi	03/17/2017	02/27/2025	President and CEO	Representative Member
Karita, Etienne	03/17/2017	02/27/2025	Clinician	Representative Member
Kates, Jennifer	03/17/2017	02/27/2025	Vice President and Director of Global Health and HIV Policy Operations & Program Manager, Global Health Programs	Representative Member
Lockett, Lejeune	03/17/2017	02/27/2025	Associate Dean for Research Co-Chair and Medical Research Director; Director of HIV Prevention Research; Professor of Medicine	Representative Member
Maxwell, Celia	03/17/2017	02/27/2025	Associate Dean for Research Co-Chair and Medical Research Director; Director of HIV Prevention Research; Professor of Medicine	Representative Member
Mayer, Kenneth	03/17/2017	02/27/2025	Associate Dean for Research Co-Chair and Medical Research Director; Director of HIV Prevention Research; Professor of Medicine	Representative Member

Milan, Jesse	03/17/2017	02/27/2025	Public Health and Leadership Consultant	Representative Member
Millett, Greg	10/01/2021	02/27/2025	vice president and director of public policy	Representative Member
Mushavi, Angela	03/17/2017	02/27/2025	National PMTCT and Pediatric HIV Care and Treatment Coordinator	Representative Member
Nabiryo, Christine	03/17/2017	02/27/2025	Director	Representative Member
Pape, Jean William	03/17/2017	02/27/2025	Professor of Medicine; Director	Representative Member
Peters, David	03/17/2017	02/27/2025	Chair and Professor, Department of International Health	Representative Member
Pillay, Yogan	10/12/2023	02/27/2025	Director of HIV and TB Delivery	Representative Member
Sanders, Edwin	03/17/2017	02/27/2025	Senior Servant and Founder	Representative Member
Sawe, Fredrick	03/17/2017	02/27/2025	Senior Deputy Director	Representative Member
Schmid, Carl	08/01/2019	02/27/2025	Dep. Executive Director	Representative Member
Swindells, Susan	10/01/2021	02/27/2025	Physician	Representative Member
Treston, Carole	03/17/2017	02/27/2025	Executive Director	Representative Member
Warren, Mitchell	03/17/2017	02/27/2025	Executive Director	Representative Member
Wiesman, John	08/01/2019	02/27/2025	Secretary of Health	Representative Member
del Rio, Carlos	03/17/2017	02/27/2025	Hubert Professor and Chair, Department of Global Health at the Rollins School of Public Health; Professor of Medicine, Division of Infectious Diseases	Representative Member

Number of Committee Members Listed: 32

Narrative Description

The Board serves the Global AIDS Coordinator (“the Coordinator”) in a solely advisory capacity concerning scientific, implementation, and policy issues related to the global response to HIV/AIDS.

These issues are of ongoing concern and serve to maximize the impact of our investments in controlling the HIV epidemic and delivering on the promise of an AIDS-free generation.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input checked="" type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input type="checkbox"/>

Outcome Comments

N/A

What are the cost savings associated with this committee?

	Checked if Applies
None	<input type="checkbox"/>
Unable to Determine	<input type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input checked="" type="checkbox"/>

Cost Savings Comments

This is not the purpose of the committee and is difficult to quantify. However, recommendations have directly contributed to programmatic efficiencies that in turn extend the value of the PEPFAR dollar.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

60

Number of Recommendations Comments

Through the FY22 reporting period, the PEPFAR Scientific Advisory Board has issued 60 recommendations. FY22 recommendations focused on the technical considerations for the implementation of HIV recency testing for surveillance, new biomedical products for HIV prevention, implementation science, use of self-testing for PrEP, and HPV testing. Through the FY23 reporting period, the PEPFAR Scientific Advisory Board convened to discuss the role of the Board during the formation of the GHSD bureau, and to discuss updates in science related to PEPFAR programs.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

88%

% of Recommendations Fully Implemented Comments

To date, approximately 88% of all recommendations have been fully implemented by the agency, and progress is being made to partially and fully implement additional recommendations.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

12%

% of Recommendations Partially Implemented Comments

Based on the broad nature of many of the recommendations issued by the Board through the FY22 reporting period, roughly 12% of recommendations are most accurately described as partially implemented.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

PEPFAR provides feedback at : <https://www.state.gov/scientific-advisory-board-pepfar/>

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

N/A

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

N/A

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input type="checkbox"/>

Access Comments

N/A